Hybrid polar compounds, of which hexamethylenebisacetamide (HMBA) is the prototype, are potent inducers of differentiation of murine erythroleukemia (MEL) 
In previous reports (1) (2) (3) (4) , we have identified a group of hybrid polar compounds that are inducers of differentiation of a variety of transformed cells. Hexamethylenebisacetamide (HMBA) is the prototype of these compounds and has been used to investigate the mechanism of action (5) and to evaluate the therapeutic efficacy of hybrid polar compounds in the control of cancer by differentiation therapy (6) . In this regard, a phase II clinical trial was conducted using HMBA to treat patients with myelodysplastic syndrome or acute myelogenous leukemia (6) . Of 28 patients, 9 achieved a complete or partial remission lasting from 1 to 16 months. These clinical studies also provided direct evidence that HMBA induces the differentiation of transformed cells in patients. In 
MATERIALS AND METHODS
Cell Culture. MEL cells (DS19) (23, 24) , the vincristineresistant variant, VCR-C15 (8, 9) , and the HMBA-resistant R1 cells (10) were maintained in minimal essential medium containing 10% fetal calf serum. Cultures were initiated from cells in logarithmic growth at 105 cells/mi. Cell density, benzidinereactivity, and commitment to terminal differentiation were assayed as described (11) . Cells were synchronized with respect to cell cycle by elutriation (12 (Table 1) were selected for further structure/function study from our laboratories' portfolio of more than 600 novel synthesized hybrid polar compounds, based upon their potency as inducers of MEL cell differentiation and structural features that might impart distinct and improved biological (and perhaps clinical) characteristics. EMBA was synthesized in a search for novel bisamides that would be more potent inducers of differentiation than the bisacetamide, HMBA, and the equipotent biscarboxamide (3) . EMBA is distinctly more active (optimal concentration 0.4 mM) (Fig. 1B) than HMBA (optimal concentration 5 mM) (Fig. 1A) , and like HMBA it induces a high proportion of MEL cells (DS19) to differentiate (Table 1) and HL-60 cells as well (data not shown). EMBA displays a broad concentration range of activity without significant cytotoxicity, as determined by cell proliferation (Fig. 1B) and trypan blue exclusion (data not shown).
As a class, the group of hydroxamic acid derivatives are significantly more potent than either HMBA or EMBA (3). We have previously described the preparation and properties of the prototypic bishydroxamic acid, suberoyl bishydroxamic acid (SBHA) (3, 4) , which, at its optimal effective concentration of 30 ,LM, is 160-fold more active than HMBA. SAHA was designed to explore the possibility that both ends of the inducer need not carry the hydroxamic group and that activity may be enhanced if one end has a hydrophobic residue. As shown in Table 1 , this is the case; SAHA, active at 2 jtM, is more than 15-fold more active than SBHA (Fig. 1C) . CBHA is yet another relative of SBHA in which, in this case, the apolar linker between the two hydroxamate groups is designed to be more rigid. This modification also retains the improved activity characteristic of the class of hydroxamic acid derivatives (Table  1) . Both SAHA and CBHA share a relatively narrow effective dose range and an abrupt fall in viable cell count across that range ( Fig. 1 C and D) .
Variant MEL cell lines with either enhanced or decreased sensitivity to hybrid polar differentiation-inducing compounds (8, 10) have previously been used in the biological evaluation of these agents. HMBA and the three second generation agents were assayed for their activities as inducers of differentiation with two of these variant cell lines derived from the parental MEL cell, DS19: VCR-C15 (8), a cell line with increased sensitivity to HMBA and R1, a cell line selected for resistance to HMBA (10) . DS19, VCR-C15, and R1 cells were cultured with each compound across a range of concentrations to determine the optimal dose for induction of differentiation and the dose effect on cell growth. VCR-C15 cells are sensitive to all three agents at a somewhat lower concentration than are the parental DS19 cells, a property these new agents share with HMBA (Fig. 1) . Of the three new agents, R1 cells display distinct cross-resistance to EMBA, whereas these HMBAresistant cells are more sensitive to induction by SAHA and Proc. Natl. Acad. Sci. USA 93 (1996) 5707 CBHA. HMBA and EMBA were also distinguished from SAHA and CBHA in their effects on cell proliferation of DS19, VCR-C15, and R1 at the concentrations optimal for inducing differentiation of these cell lines (Fig. 1) (Fig. 2) . Cells cultured without inducer have completed the first cell cycle and approximately 40% of the cells have already entered the second S phase within 12 hr after onset of culture. Less than 20% of these untreated cells are in the G1 phase after 15 hr. Cells exposed to HMBA or EMBA were predominately (>80%) in G1 at 12 hr, and remained in GI through 15 hr of culture, by which time some cells were beginning to move into S. Cells cultured with SAHA and CBHA appear to traverse the initial cell cycle at a slower rate than those cells cultured with Effect of Cytodifferentiation Agents on Proteins Regulating Cell Cycle Progression. HMBA-induced differentiation of MEL cells is accompanied by an increase in the level of inhibitors of G1 to S transition, including the underphosphorylated form of the retinoblastoma gene product (pRB) (16, 17) and the cyclin-dependent kinase inhibitor, p21 (ref. 18, F. Civoli, unpublished observation). We asked whether the induction of differentiation by EMBA, SAHA, and CBHA is also associated with changes in the levels of pRB and p21 (Fig.  3) . DS19 cells were cultured with HMBA, EMBA, SAHA, or CBHA and protein extracts prepared at 48 hr. Each of the inducers caused both an increase in the total amount of pRB protein and an increase in the underphosphorylated form of the protein. The level of p21 protein was also determined in DS19 cells at 48 hr of culture with HMBA, EMBA, SAHA, or CBHA (Fig. 3) . Each agent induced an increase in the level of p21 protein.
We and others have previously demonstrated that downregulation of the positive G1-to S-phase regulator, c-myb, is associated with and apparently critical for HMBA-induced differentiation of MEL cells (19) (20) (21) , so that the expression of c-myb protein was also studied during induction with EMBA, SAHA, and CBHA (Fig. 3) (19, 20) . The identification of agents which, though initiating other events such as hemoglobin production and cell cycle perturbations in common with HMBA, fail to utilize the c-mybrelated mechanism, suggests that significant differences in pathway controls have yet to be elucidated.
A major reason for exploring the actions of novel hybrid polar agents is to design more clinically useful differentiationinducing compounds. The identification of subset differences in biologic activity may hold promise for the development of more potent hybrid polar differentiating agents with reduced toxicity.
